Clinical trials: Monkey Pox
Smallpox, Monkeypox
Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years
The aim of the clinical study is to study the safety and tolerability of the live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus, in intracutaneous administration.
- Conditions
- Smallpox, Monkeypox, Cowpox, Vaccinia Virus Infection
- Trial name
- NCT05762523
- Testing
- VAC∆6 vaccine - оnce at a dose of 10⁶ PFU, VAC∆6 vaccine - once at a dose of 10⁷ PFU, VAC∆6 vaccine - twice at a dose of 10⁶ PFU
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"
Mpox (Monkeypox), Monkeypox Virus Infection
DiagRaMIE Mpox Virus-RDC for the Diagnostic of Monkeypox
Monkeypox, caused by a virus in the Orthopoxvirus genus, is a zoonotic disease first identified in 1970 in the Democratic Republic of Congo (DRC).
- Trial name
- DiagRaMIE Mpox (NCT06840197)
- Testing
- NG-TestⓇ Monkeypox virus kit
- Where
- 3 sites in Republic of the Congo
- Volunteers
- 197 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Monkeypox
Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC
The goal of this observational study is to monitor and assess the safety profile of the MVA-BN vaccine among staff and study personnel of the PALM-007 study in the Democratic Republic of the Congo.
- Trial name
- NCT05734508
- Testing
- MVA-BN vaccine
- Where
- 3 sites in Democratic Republic of the Congo
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox
A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
This is a randomized, double blinded, controlled phase I clinical study. To evaluate the safety and immunogenicity of receiving two doses of MVA strain monkeypox attenuated live vaccine in individuals aged 18 years and above.
- Trial name
- NCT06771479
- Testing
- MVA strain monkeypox attenuated live vaccine (low dose), MVA strain monkeypox attenuated live vaccine (high dose)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Monkey Pox
Assessing the Preparedness and Knowledge of Pharmacists in the Current Monkeypox Outbreak
General objective: to measure the preparedness of pharmacists and medical interns about monkeypox Specific objectives: to evaluate the level of knowledge among pharmacists and medical interns about monkeypox treatment and nature…
- Trial name
- NCT05543577
- Testing
- Questionnaire
- Where
- Egypt
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Beni-Suef University
Mpox
Monkeypox, Biology, Outcome, Transmission and Epidemiology -Prospective Follow-up of High-risk Contacts
With the MBOTE-CONTACT study, a detailed follow-up study of high-risk contacts of mpox patients will be done. The MBOTE-CONTACT study will be nested in the NIH-Funded PALM-007 clinical trial (NCT05559099) and the MBOTE project on…
- Trial name
- MBOTE-CONTACT (NCT06136117)
- Where
- Democratic Republic of the Congo
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Mpox (Monkeypox)
Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only
The purpose of the PALM007 extension is to further characterize the clinical and natural history of mpox, and to provide standard of care (SOC) during the ongoing outbreaks.
- Trial name
- NCT06721585
- Testing
- Tecovirimat Oral Capsule [Tpoxx], Standard of Care (SOC)
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 328 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mpox (Monkeypox)
Mpox Biology, Outcome, Transmission and Epidemiology
The MBOTE-Kamituga clinical and virological characterization protocol is a prospective observational cohort study with clinical and virological description of suspected mpox cases and longitudinal follow-up of confirmed mpox…
- Trial name
- NCT06652646
- Where
- Democratic Republic of the Congo
- Volunteers
- 1,000 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Mpox
Validation of SDS-EDTA-Treated Chromatography Paper Strips for Mpox Sampling and Transport in DRC
The objective of this prospective paired diagnostic comparison study is to evaluate the diagnostic yield and field applicability of SDS-EDTA-treated chromatography paper strips for the collection, transport, and laboratory…
- Trial name
- NCT07634081
- Testing
- SDS-EDTA-treated chromatography strip
- Where
- Democratic Republic of the Congo
- Volunteers
- 150 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Monkeypox (Mpox)
Prospective Follow-up After MVA-BN Booster Vaccination
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of…
- Trial name
- POQS-Boosted (NCT07342829)
- Where
- Belgium
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Monkeypox, HIV Infections
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which…
- Conditions
- Monkeypox, HIV Infections, AIDS
- Trial name
- VIRISMAP (NCT06045923)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Centers for Disease Control and Prevention
Monkeypox
European Trial Into Mpox Infection
The goal of this randomized controlled double-blind clinical trial is to test the drug tecovirimat in patients with mpox (previously known as monkeypox) disease.
- Trial name
- EPOXI (NCT06156566)
- Testing
- Tecovirimat Oral Capsule
- Where
- 12 sites in Belgium, France and 6 more
- Volunteers
- 150 people
- Sponsor
- Miquel Ekkelenkamp
Monkeypox
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
This study is a Phase 2 open-label, non-placebo controlled, multi-site clinical trial that will evaluate the standard SC regimen in adolescents ages 12 through 17 years, inclusive, and compared to the standard subcutaneous…
- Trial name
- NCT05740982
- Testing
- JYNNEOS
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
This study is a Phase 2 randomized, open-label, non-placebo controlled, multi-site clinical trial that will evaluate two intradermal (ID) regimens for Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine compared to the…
- Trial name
- NCT05512949
- Testing
- JYNNEOS
- Where
- 8 sites in United States
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monkey Pox
Efficacy and Acceptability of a Monkeypox Curriculum for Disproportionately Impacted Communities
The study team will create an online module via the REDCap platform. The module will include around 5 videos and several infographics covering the topics of symptoms, transmission, prevention, vaccination, and treatment of the…
- Trial name
- NCT05651581
- Testing
- Online module
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Monkey Pox, Monkeypox
Mpox Paediatric and Adolescent Clinical Study
The goal of this multicentre, observational study on mpox in infants, children and adolescents is to increase knowledge about mpox infection and its associated disease in infants, children and adolescents.
- Trial name
- NCT05947786
- Where
- 6 sites in United States, Democratic Republic of the Congo and 4 more
- Volunteers
- 1,108 people
- Sponsor
- PENTA Foundation
Monkeypox
Tecovirimat in Non-hospitalized Patients With Monkeypox
PLATINUM-CAN is a parallel collaborative trial linked with the sister trial PLATINUM led by Oxford University. PLATINUM-CAN is a multi-centre, randomized, placebo-controlled trial of Tecovirimat in non-hospitalized patients with…
- Trial name
- PLATINUM-CAN (NCT05534165)
- Testing
- Tecovirimat
- Where
- 3 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Marina Klein
Monkey Pox
Performance Evaluation of Mpox Molecular POC Diagnostics
PP016 is a FIND-sponsored retrospective clinical performance study evaluating rapid molecular point-of-care (mPOC) tests for the detection of Mpox virus (MPXV) using archived lesion swab specimens collected in Uganda.
- Trial name
- NCT07620600
- Testing
- MPOX IVD test
- Where
- Uganda
- Volunteers
- 80 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Monkeypox, Mpox
New York City Observational Study of Mpox Immunity
The goal of this study is to assess the immune response, tolerance, and safety of the low-dose intradermal (forearm) mpox vaccine in people who are HIV+ compared to people who are HIV-, and compared to the standard-dose…
- Conditions
- Monkeypox, Mpox, HIV
- Trial name
- NYC OSMI (NCT05654883)
- Where
- United States
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Smallpox, Monkeypox
Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years
The Aim: Study immunogenicity, confirm the safety and tolerability of different schedules of vaccination with "live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC∆6 vaccine) based on vaccinia virus"…
- Conditions
- Smallpox, Monkeypox, Cowpox, Vaccinia Virus Infection
- Trial name
- NCT05846243
- Testing
- VAC∆6 vaccine (10⁷ PFU), VAC∆6 vaccine (10⁶ PFU), Live Smallpox Vaccine
- Where
- 2 sites in Russia
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"